- Home
- FIGS vs JANX Comparison
FIGS vs JANX Comparison
Compare FIGS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIGS | JANX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FIGS | JANX |
|---|---|---|
| Price | $11.93 | $13.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $9.60 | ★ $60.27 |
| AVG Volume (30 Days) | 2.3M | ★ 2.3M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.65 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $581,034,000.00 | $10,000,000.00 |
| Revenue This Year | $9.08 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $110.60 | ★ N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.57 | $13.26 |
| 52 Week High | $12.35 | $61.59 |
Technical Indicators
Market Signals| Indicator | FIGS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 31.14 |
| Support Level | $11.02 | $13.26 |
| Resistance Level | $11.79 | $14.49 |
| Average True Range (ATR) | 0.41 | 0.48 |
| MACD | -0.12 | 0.41 |
| Stochastic Oscillator | 69.65 | 37.86 |
Price Performance
Historical ComparisonAbout FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.